Coram to Purchase Caremark's Home Infusion Therapy Business

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 3
Volume 4
Issue 3

DENVER--Coram Healthcare Corp. has reached a definitive agreement to acquire Caremark International's home infusion therapy business. Under the agreement, Caremark will receive approximately $310 million in cash and securities.

DENVER--Coram Healthcare Corp. has reached a definitive agreementto acquire Caremark International's home infusion therapy business.Under the agreement, Caremark will receive approximately $310million in cash and securities.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content